Patents by Inventor Mi Young Cha
Mi Young Cha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230256Abstract: The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.Type: ApplicationFiled: April 9, 2021Publication date: July 29, 2021Applicant: GENOME AND COMPANYInventors: Bu-Nam JEON, Yun Yeon KIM, Suro LEE, Youn Kyung HOUH, Joo-Yeon CHUNG, Areum JEONG, Mi Young CHA
-
Patent number: 10988482Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.Type: GrantFiled: August 13, 2015Date of Patent: April 27, 2021Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
-
Publication number: 20200062775Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.Type: ApplicationFiled: August 13, 2015Publication date: February 27, 2020Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
-
Patent number: 10562902Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.Type: GrantFiled: August 12, 2016Date of Patent: February 18, 2020Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Jiangcheng Xu, Qinguan Cai, Mi Young Cha, Maengsup Kim
-
Patent number: 10322108Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).Type: GrantFiled: January 22, 2016Date of Patent: June 18, 2019Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
-
Patent number: 10273242Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: GrantFiled: October 31, 2017Date of Patent: April 30, 2019Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Publication number: 20180244677Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.Type: ApplicationFiled: August 12, 2016Publication date: August 30, 2018Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiangcheng XU, Qinguan CAI, Mi Young CHA, Maengsup KIM
-
Publication number: 20180051036Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: ApplicationFiled: October 31, 2017Publication date: February 22, 2018Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming LIU, Mi Young CHA, Gong LI, Zhanmei LI, Hongjuan QIU, Maengsup KIM
-
Publication number: 20170368028Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).Type: ApplicationFiled: January 22, 2016Publication date: December 28, 2017Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
-
Patent number: 9840517Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: GrantFiled: September 18, 2014Date of Patent: December 12, 2017Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Publication number: 20160340422Abstract: The present invention provides a bifunctional fusion protein comprising the extracellular region of CTLA4 and an anti-IL-17 antibody, a gene encoding the protein, a vector comprising the gene, a host cell comprising the vector, and a pharmaceutical composition containing the protein.Type: ApplicationFiled: January 28, 2015Publication date: November 24, 2016Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Guoqiang Chen, Jiawang Liu, Nanmeng Song, Yaping Yang, Mi Young Cha
-
Publication number: 20160229865Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: ApplicationFiled: September 18, 2014Publication date: August 11, 2016Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Publication number: 20160229868Abstract: A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient.Type: ApplicationFiled: April 15, 2016Publication date: August 11, 2016Applicant: HANMI SCIENCE CO., LTDInventors: Mi Young CHA, Seok Jong KANG, Mi Ra KIM, Ju Yeon LEE, Ji Young JEON, Myoung Gi JO, Eun Joo KWAK, Kwang Ok LEE, Tae Hee HA, Kwee Hyun SUH, Maeng Sup KIM
-
Patent number: 9345719Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: October 23, 2014Date of Patent: May 24, 2016Assignee: Hanmi Science Co., Ltd.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Patent number: 8957065Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: June 20, 2011Date of Patent: February 17, 2015Assignee: Hanmi Science Co., LtdInventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Publication number: 20150045324Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Applicant: HANMI SCIENCE CO., LTDInventors: Mi Young CHA, Seok Jong KANG, Mi Ra KIM, Ju Yeon LEE, Ji Young JEON, Myoung Gi JO, Eun Joo KWAK, Kwang Ok LEE, Tae Hee HA, Kwee Hyun SUH, Maeng Sup KIM
-
Publication number: 20130116213Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: ApplicationFiled: June 20, 2011Publication date: May 9, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Patent number: 8188102Abstract: The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient.Type: GrantFiled: June 5, 2008Date of Patent: May 29, 2012Assignee: Hanmi Holdings Co., Ltd.Inventors: Kwang-Ok Lee, Mi Young Cha, Mi Ra Kim, Young Hee Jung, Chang Gon Lee, Se Young Kim, Keukchan Bang, Bum Woo Park, Bo Im Choi, Yun Jung Chae, Mi Young Ko, Han Kyong Kim, Young-Gil Ahn, Maeng Sup Kim, Gwan Sun Lee
-
Patent number: 8003658Abstract: The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.Type: GrantFiled: December 20, 2005Date of Patent: August 23, 2011Assignee: Hanmi Holdings Co., Ltd.Inventors: Young Jin Ham, Ji Hyeon Gong, Mi Young Cha, Jong Woo Kim, Maeng Sup Kim, Eun Young Kim, Ji Yeon Song, Chang In Kim, Se Young Kim, Gwan Sun Lee
-
Patent number: RE46511Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: April 14, 2016Date of Patent: August 15, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim